| アイテムタイプ |
リポジトリ登録用アイテムタイプ（フル）(1) |
| 公開日 |
2026-03-25 |
| タイトル |
|
|
タイトル |
A trend in anticoagulant therapy for patients with cancer-associated venous thromboembolism |
|
言語 |
en |
| 作成者 |
Satoh, Fumie
| en |
Satoh, Fumie
|
|
Department of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine
|
Search repository
Kondo, Norihiro
| en |
Kondo, Norihiro
|
|
Department of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine，Aomori City Hospital
|
Search repository
Murata, Kenyu
| en |
Murata, Kenyu
|
|
Department of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine
|
Search repository
Kawamura, Tomonori
| en |
Kawamura, Tomonori
|
|
Department of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine
|
Search repository
Minakawa, Masahito
| en |
Minakawa, Masahito
|
|
Department of Thoracic and Cardiovascular Surgery, Hirosaki University Graduate School of Medicine
|
Search repository
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective: This study aimed to evaluate the efficacy and safety of primary therapeutic agents for treating cancer- associated venous thromboembolism （VTE）. Material and Methods: Participants comprised 202 patients with active cancer and newly diagnosed VTE treated between 2014 and 2022. Patients were divided into two groups based on the treatment initiation period: early, Group E （2014–2018）; or late, Group L （2019–2022）. Outcomes were compared between groups. Results: The main anticoagulants used were edoxaban （58.5%） in Group E and rivaroxaban （36.5%） in Group L. Recurrent VTE occurred within 3 months in 7.7% （n=8） of Group E and 4.2% （n=4） of Group L. No significant differences were observed in death within 30 days, VTE-related deaths, hemorrhagic complications, or recurrent VTE. Although the overall number of deaths differed significantly between groups （Group E: 29 vs. Group L: 21; p<0.01） due to differences in mean follow-up （E: 37.4 months vs. L: 23.1 months; p<0.001）, no significant differences were found in VTE-related deaths, recurrences, or hemorrhagic complications. Conclusion: Direct oral anticoagulants play a major role and represent a safe and effective alternative to traditional anticoagulation for cancer patients with VTE. Future studies should focus on optimizing treatment duration to maximize benefits and minimize risks. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Key words: cancer VTE; DOAC |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
弘前大学大学院医学研究科 |
|
言語 |
ja |
| 出版者 |
|
|
出版者 |
Hirosaki University Graduate School of Medicine |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00211444 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0439-1721 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2434-4656 |
| 書誌情報 |
ja : 弘前医学
en : Hirosaki Medical Journal
巻 76,
号 1-4,
p. 17-24,
発行日 2026-03-10
|
Hirosaki Med J 76-1-4_17.pdf (1.3 MB)
